Second primary squamous cell carcinoma of the oral cavity - a retrospective cohort study of therapeutic procedures and oncological outcome.
OSCC
Oral cancer
Recurrence
Second primary tumor
Survival
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
26 Mar 2024
26 Mar 2024
Historique:
received:
18
01
2024
accepted:
09
03
2024
medline:
26
3
2024
pubmed:
26
3
2024
entrez:
26
3
2024
Statut:
epublish
Résumé
In the presented study, the occurrence rates of second primary oral carcinomas and their prognostic relevance were analyzed. All patients with surgically treated oral squamous cell carcinomas within the years 2010 and 2022 in our department were included in this retrospective cohort study. Two groups were designed including patients with second primary carcinomas and patients with local tumor recurrences. Occurrence rates, tumor stages and applied therapies were assessed. Primary outcome was overall survival in dependence of the index tumor. Secondary outcomes were overall survival in dependence of local recurrences or second primary tumors. An overall number of 908 patients was included in the analysis. 98 patients (10.8%) developed a second primary oral squamous cell carcinoma. Patients with second primary tumors presented significantly (p < 0.001) better overall survival in dependence of the index tumor compared to patients suffering from local recurrences. There was no significant difference in overall survival (p = 0.4) in dependence of the date of second primary tumor or local recurrence. Patients with second primary tumors were more likely to receive surgery-based therapy compared to patients with local recurrences who more frequently received definitive radiotherapy. Our data indicates different clinical courses in terms of therapy and survival of patients suffering from second primary tumors compared to patients with local tumor recurrences. This may be due to a more aggressive biology of local recurrences and earlier detection of second primaries due to oncological follow-up of the index tumor. The differentiation of local tumor recurrences and second primary tumors is of clinical relevance, as applicable therapies and resulting prognosis may differ significantly.
Identifiants
pubmed: 38530421
doi: 10.1007/s00784-024-05606-5
pii: 10.1007/s00784-024-05606-5
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
229Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Siegel RL et al (2021) Cancer Statistics, CA Cancer J Clin, 2021. 71(1): p. 7–33
Shield KD et al (2017) The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA Cancer J Clin 67(1):51–64
doi: 10.3322/caac.21384
pubmed: 28076666
Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386
doi: 10.1002/ijc.29210
pubmed: 25220842
Nokovitch L et al (2023) Oral cavity squamous cell carcinoma risk factors: state of the art. J Clin Med, 12(9)
Slaughter DP, Southwick HW, Smejkal W (1953) Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6(5):963–968
doi: 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
pubmed: 13094644
Cooper JS et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19):1937–1944
doi: 10.1056/NEJMoa032646
pubmed: 15128893
Moratin J et al (2020) The prognostic significance of the lymph node ratio in oral cancer differs for anatomical subsites. Int J Oral Maxillofac Surg 49(5):558–563
doi: 10.1016/j.ijom.2019.10.015
pubmed: 31740138
Ferris RL et al (2016) Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375(19):1856–1867
doi: 10.1056/NEJMoa1602252
pubmed: 27718784
pmcid: 5564292
Burtness B et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394(10212):1915–1928
doi: 10.1016/S0140-6736(19)32591-7
pubmed: 31679945
Horn D et al (2020) Prospective feasibility analysis of salvage surgery in recurrent oral cancer in terms of quality of life. Oral Oncol 102:104580
doi: 10.1016/j.oraloncology.2020.104580
pubmed: 31991265
Zittel S et al (2022) Clinical outcome and prognostic factors in recurrent oral squamous cell carcinoma after primary surgical treatment: a retrospective study. Clin Oral Investig 26(2):2055–2064
doi: 10.1007/s00784-021-04186-y
pubmed: 34581884
Suton P et al (2018) Outcomes for patients with second primary malignancy after primary surgical treatment for early-stage squamous cell carcinoma of the oral cavity. Head Neck 40(11):2347–2352
doi: 10.1002/hed.25330
pubmed: 30302872
van der Waal I, de Bree R (2010) Second primary tumours in oral cancer. Oral Oncol 46(6):426–428
doi: 10.1016/j.oraloncology.2010.02.018
pubmed: 20308001
Rennemo E, Zatterstrom U, Boysen M (2010) Outcome of local failures after oral cancer - recurrence vs. second primary. J Oral Pathol Med 39(9):657–661
doi: 10.1111/j.1600-0714.2010.00905.x
pubmed: 20618618
Rogers SN et al (2019) Incidence, timing, presentation, treatment, and outcomes of second primary head and neck squamous cell carcinoma after oral cancer. Br J Oral Maxillofac Surg 57(10):1074–1080
doi: 10.1016/j.bjoms.2019.09.018
pubmed: 31611034
de Vries N, Van der Waal I, Snow GB (1986) Multiple primary tumours in oral cancer. Int J Oral Maxillofac Surg 15(1):85–87
doi: 10.1016/S0300-9785(86)80015-1
pubmed: 3083010
Warren SJAJc (1932) Multiple primary malignant tumors: a survey of the literature and statistical study. 51:1358–1403
Mroueh R et al (2020) Risk of second primary cancer in oral squamous cell carcinoma. Head Neck 42(8):1848–1858
doi: 10.1002/hed.26107
pubmed: 32057158
Min SK et al (2019) Second primary cancers in patients with oral cavity cancer included in the Korea Central Cancer Registry. Oral Oncol 95:16–28
doi: 10.1016/j.oraloncology.2019.05.025
pubmed: 31345385
Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13(Suppl 1):S31–s34
doi: 10.4103/sja.SJA_543_18
pubmed: 30930717
pmcid: 6398292
Tiwana MS et al (2014) Incidence of second metachronous head and neck cancers: population-based outcomes over 25 years. Laryngoscope 124(10):2287–2291
doi: 10.1002/lary.24719
pubmed: 24729185
Kaur P et al (2016) A retrospective evaluation of Clinical Profile of Second Primary Head and Neck Cancer. J Clin Diagn Res 10(10):XC10–XC14
pubmed: 27891442
Brands MT et al (2019) Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer. Cancer Med 8(12):5810–5819
doi: 10.1002/cam4.2124
pubmed: 31400079
pmcid: 6745868
Kesting MR et al (2009) Bronchoscopy screening in primary oral squamous cell carcinoma: a 10-year experience. Br J Oral Maxillofac Surg 47(4):279–283
doi: 10.1016/j.bjoms.2009.01.009
pubmed: 19243866
Kesting MR et al (2009) Results of esophagogastroduodenoscopy in patients with oral squamous cell carcinoma–value of endoscopic screening: 10-year experience. J Oral Maxillofac Surg 67(8):1649–1655
doi: 10.1016/j.joms.2009.04.061
pubmed: 19615577
Metzger K et al (2019) Is panendoscopy a necessary staging procedure in patients with lacking risk factors and oral squamous cell carcinoma? J Craniomaxillofac Surg 47(12):1968–1972
doi: 10.1016/j.jcms.2019.11.009
pubmed: 31810847
Weckx A et al (2019) Time to recurrence and patient survival in recurrent oral squamous cell carcinoma. Oral Oncol 94:8–13
doi: 10.1016/j.oraloncology.2019.05.002
pubmed: 31178216
Sun GW et al (2009) Salvage treatment for recurrent oral squamous cell carcinoma. J Craniofac Surg 20(4):1093–1096
doi: 10.1097/SCS.0b013e3181abb307
pubmed: 19521259
Mucke T et al (2009) Recurrence interval affects survival after local relapse of oral cancer. Oral Oncol 45(8):687–691
doi: 10.1016/j.oraloncology.2008.10.011
pubmed: 19095488
Masuda M et al (2013) Somatic evolution of head and neck cancer - biological robustness and latent vulnerability. Mol Oncol 7(1):14–28
doi: 10.1016/j.molonc.2012.10.009
pubmed: 23168041
Leemans CR, Snijders PJF, Brakenhoff RH (2018) The molecular landscape of head and neck cancer. Nat Rev Cancer 18(5):269–282
doi: 10.1038/nrc.2018.11
pubmed: 29497144
Johnson DE et al (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92
doi: 10.1038/s41572-020-00224-3
pubmed: 33243986
pmcid: 7944998
Horn D et al (2016) Outcome of heavily pretreated recurrent oral squamous cell carcinoma after salvage resection: a monocentric retrospective analysis. J Craniomaxillofac Surg 44(8):1061–1066
doi: 10.1016/j.jcms.2016.05.005
pubmed: 27255408
Moratin J et al (2021) Full-thickness tumor resection of oral Cancer involving the facial skin-Microsurgical Reconstruction of extensive defects after Radical Treatment of Advanced Squamous Cell Carcinoma. Cancers (Basel), 13(9).
Held T et al (2020) Carbon ion reirradiation compared to intensity-modulated re-radiotherapy for recurrent head and neck cancer (CARE): a randomized controlled trial. Radiat Oncol 15(1):190
doi: 10.1186/s13014-020-01625-0
pubmed: 32758267
pmcid: 7405378
Held T et al (2022) Ways to unravel the clinical potential of carbon ions for head and neck cancer reirradiation: dosimetric comparison and local failure pattern analysis as part of the prospective randomized CARE trial. Radiat Oncol 17(1):121
doi: 10.1186/s13014-022-02093-4
pubmed: 35804448
pmcid: 9264522